Accounting for intra-species variability in drug exposure and residues with physiologically-based pharmacokinetic modeling

被引：0
|
作者：
Taverne, F. J. [1 ]
Gehring, R. [1 ]
Meijer, B. [2 ]
Heederik, D. J. J. [1 ]
Mouton, J. W. [3 ]
Kramer, N. I. [1 ]
机构：
[1] Univ Utrecht, Inst Risk Assessment Sci, Utrecht, Netherlands
[2] Dopharma Res BV, Raamsdonksveer, Netherlands
[3] Erasmus MC, Dept Med Microbiol & Infect Dis, Rotterdam, Netherlands
来源：
JOURNAL OF VETERINARY PHARMACOLOGY AND THERAPEUTICS | 2018年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
P13.6
引用
收藏
页码：148 / 148
页数：1
相关论文
共 50 条
  • [31] Physiologically-based pharmacokinetic modeling of target-mediated drug disposition of bortezomib in mice
    Li Zhang
    Donald E. Mager
    Journal of Pharmacokinetics and Pharmacodynamics, 2015, 42 : 541 - 552
  • [32] A best practice framework for applying physiologically-based pharmacokinetic modeling to pediatric drug development
    Johnson, Trevor N.
    Small, Ben G.
    Berglund, Eva Gil
    Rowland Yeo, Karen
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2021, 10 (09): : 967 - 972
  • [33] Gestational changes in buprenorphine exposure: A physiologically-based pharmacokinetic analysis
    Zhang, Hongfei
    Kalluri, Hari V.
    Bastian, Jaime R.
    Chen, Huijun
    Alshabi, Ali
    Caritis, Steve N.
    Venkataramanan, Raman
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (09) : 2075 - 2087
  • [34] Prediction of gastric pH-mediated drug exposure using physiologically-based pharmacokinetic modeling: A case study of itraconazole
    Yang, Eunsol
    Yu, Kyung-Sang
    Lee, SeungHwan
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2023, 12 (06): : 865 - 877
  • [35] PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING (PBPK) OF PITAVASTATIN AND ATORVASTATIN TO PREDICT DRUG-DRUG INTERACTIONS (DDIS).
    Duan, P.
    Zhao, P.
    Zhang, L.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2015, 97 : S16 - S17
  • [36] Modeling the complexity of drug-drug interactions: A physiologically-based pharmacokinetic study of Lenvatinib with Schisantherin A/Schisandrin A
    Zheng, Aole
    Yang, Dongsheng
    Pan, Chunyang
    He, Qingfeng
    Zhu, Xiao
    Xiang, Xiaoqiang
    Ji, Peiying
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2024, 196
  • [37] Evaluation of the drug-drug interaction potential of brigatinib using a physiologically-based pharmacokinetic modeling approach
    Hanley, Michael J.
    Yeo, Karen Rowland
    Tugnait, Meera
    Iwasaki, Shinji
    Narasimhan, Narayana
    Zhang, Pingkuan
    Venkatakrishnan, Karthik
    Gupta, Neeraj
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 624 - 637
  • [38] Ribociclib Drug-Drug Interactions: Clinical Evaluations and Physiologically-Based Pharmacokinetic Modeling to Guide Drug Labeling
    Samant, Tanay S.
    Huth, Felix
    Umehara, Kenichi
    Schiller, Hilmar
    Dhuria, Shyeilla, V
    Elmeliegy, Mohamed
    Miller, Michelle
    Chakraborty, Abhijit
    Heimbach, Tycho
    He, Handan
    Ji, Yan
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 108 (03) : 575 - 585
  • [39] Physiologically-based pharmacokinetic modeling of prominent oral contraceptive agents and applications in drug-drug interactions
    Lewis, Gareth J.
    Ahire, Deepak
    Taskar, Kunal S.
    CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (04): : 563 - 575
  • [40] Physiologically-based pharmacokinetic modeling for absorption, transport, metabolism and excretion
    K. Sandy Pang
    Matthew R. Durk
    Journal of Pharmacokinetics and Pharmacodynamics, 2010, 37 : 591 - 615
12345